CLINICAL CHARACTERISTICS AND OUTCOMES OF COVID-19 ASSOCIATED WITH COMORBIDITIES

A retrospective analysis of the medical records of 190 COVID-19 (ICD code U07.1) patients treated in a Moscow City Clinical Hospital from May to June 2020. An overview of the spectrum of clinical manifestations of COVID-19 among the observed patients showed that the most common symptoms were fever, dry cough, dyspnoea, and sore throat. A total of 69.5% of patients tested SARS-Cov-2 positive on RNA extracted from nasopharyngeal mucus by reverse transcriptase polymerase chain reaction (RT-PCR) test, 23.7% were found to be positive by immunofluorescence assay (IFA) (detection of IgG and IgM antibodies), and 6.8% were diagnosed with typical clinical features and typical chest CT abnormalities before hospitalization, during the treatment all patients found to be PCR-positive. According to temporary clinical recommendations (version 6 effective 28 April 2020), the patients were divided into subgroups based on disease severity (severe and moderate). Clinical, epidemiological, laboratory, and instrumental data were analyzed. The comparison of moderate disease severity cases (n=119, 62.6%) and severe cases (n=71, 37.4%) detected statistically significant factors supporting the increased risk of severe illness such as cardiovascular disease, chronic kidney disease, and cerebrovascular disease. Patients aged>75 years had a strong correlation with mortality risk P<0.001. Therefore, patients with pre-existing comorbidities such as cardiovascular disease, chronic kidney disease, and cerebrovascular disease are at an increased risk of severe COVID-19. In patients older than 75 years, the risk of fatal outcome was the highest P<0.001.

Keywords:

:COVID-19, SARS-CoV-2, risk factors, comorbidities, cardiovascular disease, chronic kidney disease, cerebrovascular disease

(1) Guan WJ, NiZ Y, Hu Y, Liang WH, CQ O, JX H, Liu L, Shan H, Lei CL, Hui DSC et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708-720.doi:10.1056/NEJMoa2002032. (2) Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, Nguyen TT, Cao TM, Pham QD. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 2020; 382(9):872-874. doi:10.1056/NEJMc2001272. (3) Viner RM, Ward JL, Hudson LD, Ashe M, Patel SV, Hargreaves D, Whittaker E. Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents. Arch Dis Child. 2020; archdischild-2020-320972.doi: 10.1136/archdischild-2020-320972. (4) Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506.doi:10.1016/S0140-6736(20)30183-5. (5) Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844-847.doi:10.1111/jth.14768. (6) Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020; 55(5). doi:10.1183/13993003.00547-2020,32217650. (7) Rasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, Bonanomi E, Cabrini L, Carlesso E, Castelli G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020; 180(10):1345-1355. doi:10.1001/jamainternmed.2020.3539. (8) Docherty AB, et al. Features of 20133UK patients in hospital with covid-19 using the ISARICWHO Clinical Characterization Protocol: prospective observational cohort study. Br Med J. 2020; 369: m1985. (9) Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 2020; 17(9): 543–558.doi:10.1038/s41569-020-0413-9. (10) Wang DW, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Heng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-1069. doi:10.1001/jama.2020.1585. (11) Ansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol. 2020; 16(12):705-706.doi:10.1038/s41581-020-00349-4. (12) Barbu MG, Thompson RJ, Thompson DC, Cretoiu D, Suciu N. The impact of SARS-CoV-2 on the most common comorbidities-a retrospective study on 814 COVID-19 deaths in Romania. Front Med. Lausanne. 2020; 7: 567199. doi:10.3389/fmed.2020.567199. (13) Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M. Comorbidity and its impact on patients with COVID-19 SN Compr Clin Med. 2020; 1: 1–8. doi:10.1007/s42399-020-00363-4. (14) Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020; 99: 47-56. doi:10.1016/j.ijid.2020.07.029. (15) Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054-1062.doi:10.1016/S0140-6736(20)30566-3. (16) Ranieri VM, Rubenfeld GD, Thompson BT, et al.. ARDS Definition Task Force: Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012; 307(23): 2526-2533. doi:10.1001/jama.2012.5669. (17) Kamkin EG. Interim guidelines. Prevention, diagnostics and treatment of new coronavirus infection (COVID-19). Russian Ministry of Health. 2020. (18) Omori R, Matsuyama R, Nakata Y. The age distribution of mortality from novel coronavirus disease (COVID-19) suggests no large difference of susceptibility by age [Sci. rep.]. Sci Rep. 2020; 10(1): 16642.doi:10.1038/s41598-020-73777-8. (19) Phelps M, Christensen DM, Gerds T, Fosbøl E, Torp-Pedersen C, Schou M, Køber L, Kragholm K, Andersson C, et al. Cardiovascular comorbidities as predictors for severe COVID-19 infection or death. EHJ-QCCO. 2021; 7(2): 172-180. doi:10.1093/ehjqcco/qcaa081. (20) Guan WJ, Liang WH, He JX, Zhong NS. Cardiovascular comorbidity and its impact on 324 patients with COVID-19. Eur Respir J. 2020; 55(6): 2001227.doi:10.1183/13993003.01227-2020. (21) Paliogiannis P, Mangoni AA, Dettori P, Nasrallah GK, Pintus G, Zinellu A. D-dimer concentrations and COVID-19 severity: A systematic review and meta-analysis. Front Public Health. 2020; 8: 432. doi:10.3389/fpubh.2020.00432. (22) Liu X, Zhang R, He G. Hematological findings in coronavirus disease 2019: indications of progression of disease. Ann Hematol. 2020; 99(7): 1421-1428.doi:10.1007/s00277-020-04103-5. (23) Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, Lippi G. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020; 38(9): 1722-1726. doi:10.1016/j.ajem.2020.05.073. (24) Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, Li Y, Li T, Zhang S, Wu C, et al. C-reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infect Dis. 2020; 7(5): ofaa153.doi:10.1093/ofid/ofaa153. (25) Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020; 19(1): 18.doi:10.1186/s12941-020-00362-2.